Growing evidence suggests an association between sleep-disordered breathing (SDB) and cognitive decline in elderly persons. However, results from population-based studies have been conflicting, possibly owing to different methods to assess SDB or cognitive domains, making it difficult to draw conclusions on this association.
S leep-disordered breathing (SDB) is a very common but treatable condition in older adults. There has been growing interest in the relationship between SDB and adverse health consequences, including hypertension, diabetes, and cardiovascular diseases. [1] [2] [3] [4] While the association between SDB and health outcomes remains controversial, especially in older populations, [5] [6] [7] [8] recent evidence has suggested a link between SDB and cognitive decline in elderly persons. [9] [10] [11] Notably, most early studies have examined the association between SDB and cognition in clinical populations, eg, among patients at sleep clinics. [12] [13] [14] These studies usually consist of individuals with relatively severe SDB and were limited by small sample sizes and failure to account for confounding factors.
Over the past few years, an increasing number of population-based studies have been conducted on SDB and cognitive impairment. [15] [16] [17] These community-dwelling samples often include individuals with milder SDB, as opposed to those examined in case-control studies. Some of these studies suggested that SDB was associated with increased risk of dementia or impairment across different cognitive domains, [18] [19] [20] while others found no association. 17, 21 Owing to different study designs and methods to assess SDB, it is difficult to draw conclusions on the consistency of the associations. Moreover, because each study has reported on specific domains using different scales, it is unclear if SDB has differential effects on cognitive domains. Therefore, a meta-analytic approach is particularly useful for synthesizing these studies and elucidating pooled estimates for the effects of SDB on risk of cognitive impairment as well as effects across different cognitive domains. Given the high prevalence of cognitive impairment in elderly persons and its significant consequences, 22, 23 it is critical to explore the role of SDB as a modifiable risk factor.
Methods

Search Strategy and Study Selection
We searched for articles published before January 2017 using electronic databases, including PubMed, EMBASE, and PsychINFO, and hand searched the reference lists of identified articles. Studies were identified using the search terms "(sleep-disordered breathing OR sleep apnea OR obstructive sleep apnea) AND (cognition OR cognitive function OR cognitive decline OR dementia OR Alzheimer's OR cognitive impairment)." The search was restricted to articles published in English. Studies were included if they (1) were original articles published in a peer-reviewed journal; (2) used a crosssectional or prospective cohort design; (3) were conducted in population-based samples (N ≥ 200; mean age ≥40 years); (4) defined SDB by apnea-hypopnea index (AHI) or clinical diagnosis by International Classification of Diseases, Ninth Revision (ICD-9) codes; (5) incorporated outcomes on Alzheimer disease (AD), dementia risk, or cognitive impairment, as defined by validated cognitive tests; (6) reported effect estimates appropriate for the pooled analysis of effect sizes (eg, odds ratios [ORs], hazard ratios, mean differences, or standardized mean differences [SMDs] in cognitive test scores) or other types of estimates (eg, correlation or regression coefficient) that could be converted to the above forms; and (7) presented results adjusted for covariates (at least by age, sex, and education). Studies were excluded if they (1) were case reports, abstracts, reviews, or meta-analyses; (2) were conducted in clinical populations; (3) used case-control design; (4) used self-reported SDB; or (5) reported the prevalence of SDB rather than studying SDB as a risk factor.
Data Extraction and Cognitive Outcomes
The eligibility of the studies to be included in the analysis was determined and data were extracted independently by 2 investigators (Y.L. and C.T.M.). If multiple articles were published from the same cohort reporting on the same cognitive outcomes, we included only the one with the most complete details; if multiple articles from the same cohort had different study designs or if they reported on different cognitive outcomes, we included each of these articles separately in the analysis. Differences in data extraction between the extractors were resolved by consensus discussion and consultation with a third investigator (K.Y.). Because most prospective studies reported the OR or hazard ratio for cognitive impairment, 15, 18, [24] [25] [26] risk ratio estimates were extracted from these studies. To quantify the association between SDB and different cognitive domains, we extracted the adjusted cognitive test scores from the crosssectional studies. 17, [27] [28] [29] [30] We also obtained adjusted estimates from Nikodemova et al 31 and Hrubos-Strøm et al 32 by contacting the study authors. To be included in the pooled analysis, a cognitive domain has to be represented by more than 3 studies; thus, we focused on 3 cognitive domains: global function, delayed memory (unless the study only assessed immediate memory), and executive function. These domains are also particularly important in the context of aging and development of AD. The cognitive tests included from each study are summarized in Table 1 and Table 2 .
Definition of SDB
We included studies that used AHI or ICD-9 codes to define SDB. Apnea-hypopnea index is the average number of apnea and hypopnea events per hour of sleep. In general, hypopnea is defined as a discernible reduction in the airflow followed by at least a 4% reduction in oxyhemoglobin saturation (AHI4%), at least
Key Points
Question What are the effects of sleep-disordered breathing (SDB) on cognitive function and risk of cognitive impairment?
Findings In this systematic review meta-analysis that included more than 4 million participants, those with SDB were 26% more likely to develop cognitive impairment than those without SDB. They also had slightly worse performance in executive function but not in global cognition or memory.
Meaning Sleep-disordered breathing may be an important modifiable risk factor for dementia and other cognitive impairment; future studies are needed to examine if treatment of SDB might reduce risk of cognitive impairment.
a 3% reduction (AHI3%), or an event-related arousal (AHI3a that did not provide sufficient information for analysis by this cutoff, we contacted study authors or used other literature to obtain necessary information for the calculation.
Statistical Analysis
We pooled risk ratios to summarize the prospective relationship between SDB and cognitive impairment. One prospective study 17 reported the changes in z scores of 3 cognitive tests that were strongly associated with AD or vascular dementia; we converted the mean z scores of these tests into a single risk ratio using the online meta-analysis calculator (David B.
Wilson, PhD; http://www.campbellcollaboration.org/escalc /html/EffectSizeCalculator-OR5.php).
For cross-sectional studies, we calculated SMD in cognitive test scores by SDB status. In cases where a higher score indicated worse cognition, we multiplied the score by −1 so that high scores indicated better performance across all tests. One study 34 only reported the OR, and this was converted to
Cohen d using the formula SMD = log(OR) × ͙3 / π. For one study 29 where neither the SDs nor the 95% CIs were reported, we used the SD of the same test from another previous study. 21 To estimate the pooled SMD for each cognitive domain, we first calculated a summary Hedges g estimate for each domain from each individual source study. This step ensures that multiple relevant tests within each source study were all considered in the analysis without being overrepresented in the pooled analysis. All effect estimates were then pooled using a weighted random-effects model. We tested between-study heterogeneity using I 2 statistics 35 and used Egger test and funnel plot asymmetry to evaluate publication bias. 36 All tests were 2-tailed. Sensitivity analysis was conducted by excluding the studies that introduced significant heterogeneity to the analysis on each cognitive outcome. The quality of the included studies was evaluated independently by 2 investigators (Y.L. and C.T.M.) using the Newcastle-Ottawa Quality Assessment Scale. 37 Our study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 38 and the Metaanalysis of Observational Studies in Epidemiology (MOOSE) checklist. 39 All statistical analysis was performed using Review Manager Software version 5 (Cochrane Collaboration). Significance was set at P < .05.
Results
Literature Search and Study Characteristics
We identified a total of 3527 articles, including 1347 articles from PubMed, 359 from PsychINFO, and 1821 from EMBASE. 
Prospective Studies of SDB and Risk of Cognitive Impairment
Pooled analysis of the 6 prospective studies (including 212 943 participants) indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment, defined by clinically relevant cognitive decline 15, 17, 25 or risk of dementia, 18, 24, 26 with no evidence of publication bias but significant between-study heterogeneity ( Figure 1) . The 3 prospective studies that showed positive findings all examined risk of mild cognitive impairment (MCI) or dementia as the outcome, 18,24,26 and 2 of these used ICD-9 codes to define SDB. 24, 26 Sensitivity analysis shows that after removing the study by Blackwell et al 15 from this pooled analysis, the heterogeneity disappeared (risk ratio, 1.35; 95% CI, 1.11-1.65).
Cross-sectional Studies
Global Cognition Pooled analysis of 6 cross-sectional studies (including 4 073 604 participants) suggested that SDB was not significantly associated with global cognition (SMD, −0.02; 95% CI, −0.07 to 0.04) (Figure 2A ). There was no evidence of publication bias but significant heterogeneity between studies. Af- 
Executive Function
Pooled analysis of 7 cross-sectional studies (including 15 220 participants) indicated that those with SDB had worse executive function compared with those without (SMD, −0.05; 95% CI, −0.09 to 0.00) ( Figure 2B ). There was no evidence of heterogeneity or publication bias.
Memory Figure 2C shows the relationship between SDB and memory. One study only examined immediate memory, 32 while the rest assessed delayed recall. 16, 17, 28, 31 Pooled analysis of 5 crosssectional studies (including 11 863 participants) indicated an SMD of −0.01 (95% CI, −0.05 to 0.04) in memory score between those with and without SDB. There was no evidence of heterogeneity or publication bias.
Discussion
To our knowledge, this study is the first to provide a comprehensive systematic review and quantitative synthesis of population-based studies on SDB and cognitive function and to obtain pooled estimates of the effects of SDB on both the risk of cognitive impairment and on different domains of cognitive function. Our pooled analysis of more than 4 million adults showed that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment and had slightly worse performance in executive function but not on global cognition or memory. Although some betweenstudy heterogeneity was found, sensitivity analysis confirmed these associations, and there was no evidence of publication bias. Our findings provide evidence that SDB may be an important modifiable risk factor for cognitive impairment in elderly persons. Notably, a 2017 study 40 suggested that SDB might lead to early but possibly modifiable AD biomarker changes. Our results are also supported by a 2016 metaanalysis of case-control studies, 41 which suggested that patients with AD were 5-fold more likely to have SDB compared with cognitively intact individuals of similar age. In our metaanalysis, the 3 prospective studies 18, 24, 26 that examined the risk of MCI or dementia as the outcomes showed significant associations while the other 3 studies 15,17,25 that did not find any association all defined cognitive impairment as a significant cognitive decline. This could be owing to the differences in these cognitive outcomes, given that the severity of cognitive impairment indicated by even a significant decline in cognitive scores might not be comparable with that of clinically diagnosed MCI or dementia. It is also possible that SDB might be particularly important through the course of conversion to MCI or dementia. However, to our knowledge, the underlying cause of this observation has yet to be determined. Furthermore, studies that found significant results mostly used clinical diagnosis of SDB rather than an AHI of 15 or greater. 24, 26 This could be because the more severe cases are more likely to be detected and less likely to be misclassified or because there exist mechanistic pathways through which severe SDB could particularly impair cognition. Sensitivity analysis showed similar results after removing the study 15 that introduced significant heterogeneity to the pooled analysis of prospective studies. This heterogeneity might be because of specific characteristics of the study sample (all older men) 15 or relatively short follow-up length compared with other similar studies. 17, 25 The pooled analysis of cross-sectional studies suggests that there was a modest association between SDB and worse executive function but not with global cognition or memory. This is in line with 2 previous meta-analyses of clinical studies, 42, 43 which indicated an effect of SDB on executive function, vigilance, and psychomotor speed, while mixed findings have been reported on the effects of SDB on memory. [42] [43] [44] Notably, the included studies used cognitive tests that varied in the difficulty of administration. Moreover, not all studies examined the same cognitive domains, and even those that studied similar domains might have used different measures of that domain. This is particularly an issue for executive function, where certain components might be more vulnerable to the negative effects of SDB. Therefore, these findings should be interpreted with caution. Several mechanisms have been proposed for the association between SDB and neurocognitive decline, including All effect estimates were pooled using a weighted random-effects model. Two included studies indicated that the effects of SDB on cognition were more pronounced in APOE4 carriers. 30, 31 While the exact mechanisms for the interaction between SDB and APOE4 on cognition are unclear, the presence of APOE4 genotype is believed to increase cellular vulnerability to oxidative damage and promote neuroinflammation. 51, 52 More studies are needed to investigate the combined effects of APOE4 and SDB on cognition and to help understand potential mechanisms of their interaction.
Limitations
A few factors limit the interpretation of our results. First, the limited amount of empirical data that is appropriate for inclusion in the meta-analysis has led to a few problems. For example, prospective studies that examined "clinically significant" cognitive decline and MCI or dementia were analyzed in the same model, despite the differences between these outcomes. However, sensitivity analysis showed similar results after removing the heterogeneity from the analysis. We focused on summarizing cross-sectional evidence on 3 broad cognitive domains owing to a limited number of studies that examined detailed components of the cognitive domain and the variations in the cognitive tests administered. Although some evidence was found on the relationship between SDB and executive function, the clinical relevance of these findings is unclear, given the modest effect sizes. Future studies should use comprehensive neuropsychological test batteries, and a greater number of studies is needed to examine the effects of SDB on specific cognitive abilities more carefully. The scarce information from existing studies has also limited our ability to perform subgroup analysis, eg, by age. Given the potential differences in SDB phenotypes among younger vs older populations, 5, 53, 54 our analysis on the mixture of middleaged and older populations might have led to underestimation of the overall association, and we were unable to differentiate the cognitive effects of SDB in different age groups. Besides, to control for confounding, we included only the most adjusted model within each study. However, the level of adjustment in each study was different, and many studies have failed to consider potentially important confounders, such as body mass index. Therefore, residual confounding remains a possibility. Finally, we used a clinical diagnosis or an AHI of 15 or greater to define SDB in the pooled analysis, as this is the cutoff used by most previous studies. 33 This could have introduced misclassification that dilutes the association, especially given that the 3 different methods of scoring hypopneas could yield significantly different AHI values. 55 Because there were not enough studies for meta-analysis if we were to perform the analysis separately for AHI3%, AHI3a, and AHI4%, we chose to use 1 cutoff in the analysis but have presented these methods narratively. This approach has also limited our ability to examine the association between the severity of SDB and cognitive outcomes. It is possible that while no association was found between certain cognitive domains and the dichotomized AHI, more severe SDB or other indicators of hypoxemia might be associated with significantly worse cognition. Future epidemiologic studies should consider continuous measures of AHI to minimize the possibility of misclassification and to reveal more information about the severity of SDB.
Conclusions
In summary, this meta-analysis of population-based studies suggests that individuals with SDB are 26% more likely to develop cognitive impairment. Given the high prevalence of both cognitive impairment and SDB, these findings could have significant clinical implications. Identification of SDB in elderly persons might help to predict future risk of cognitive impairment. Clinicians should closely follow patients who experience significant levels of SDB for the occurrence of cognitive dysfunction and might consider administering full neuropsychological batteries in some instances. This is potentially important for the early detection of dementia.
Future studies are required to examine whether treatment of SDB could benefit cognition and to explore underlying mechanisms. Ultimately, this might open up new opportunities for the prevention of cognitive decline and dementia in elderly persons.
